ICM
TXG icon

Invenomic Capital Management’s 10x Genomics TXG Stock Holding History

Invenomic Capital Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-236,064
Closed -$2.73M – 180
2025
Q2 		$2.73M Buy
+236,064
New +$2.15M 0.16% 126
2025
Q1 		– Sell
-189,221
Closed -$2.72M – 202
2024
Q4 		$2.72M Buy
+189,221
New +$2.99M 0.13% 138

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Invenomic Capital Management's TXG Position: Q3 2025 in Review

Invenomic Capital Management sold out of 10x Genomics (TXG) in Q3 2025, closing a stake of 236,064 shares — an estimated $2.73M sold.

Invenomic Capital Management first reported a position in TXG in Q4 2024 and held it in 2 quarters. The position peaked at $2.73M in Q2 2025. 317 funds tracked by Wall St. Rank hold TXG as of Q3 2025.

  • Invenomic Capital Management reported no remaining 10x Genomics position as of Q3 2025 after selling out during the quarter.
  • Invenomic Capital Management sold 236,064 10x Genomics shares in Q3 2025, an estimated $2.73M.
  • Invenomic Capital Management first reported a position in 10x Genomics in Q4 2024 and held it in 2 quarters.
  • Invenomic Capital Management's 10x Genomics position peaked at $2.73M in Q2 2025.
  • 317 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2025.

Based on Invenomic Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.